Eos Energy Enterprises Inc vs BIO-TECHNE Corp — how do they compare? Eos Energy Enterprises Inc trades at $4.21 (market cap $1.47B), while BIO-TECHNE Corp trades at $72.16 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 7.6× Eos Energy Enterprises Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | TECH | |
|---|---|---|
Market Cap | $1.47B | $11.24B |
Sector | Energy | Health |
52-Week High | $19.19 | $72.29 |
52-Week Low | $3.14 | $43.31 |
Enterprise Value | $1.81B | $11.32B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.15, up 5.33% today, but faces significant financial challenges with a net income margin of -246.76% and negative cash flow from operations. The company reported record Q2 2026 revenue but missed earnings expectations with a $1.20 per share loss. Technical indicators show a mixed picture with bullish overall signals but bearish moving averages, while analyst sentiment remains cautious with 70% hold ratings.
Despite revenue growth potential in the energy storage market, EOSE carries substantial risk due to persistent losses, high debt-to-asset ratio of 91.87%, and ongoing shareholder litigation. The consensus price target of $7.75 suggests upside potential, but investors should weigh the company's financial instability against its growth prospects in the competitive battery storage sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →